Agoracom Blog Home

Posts Tagged ‘cannabinoids’

#CBD Oil and Skin Care: What You Need To Know – SPONSOR: Avicanna $AVCN.ca $AVCNF $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 4:13 PM on Wednesday, December 2nd, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: ONN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

CBD Oil and Skin Care: What You Need To Know

  • Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health.
  • As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.
  • Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising.
  • The antioxidants can help reduce the signs and impacts associated with aging.
  • The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.

By: Natalie Gray November 30, 2020

CBD oil is one of the active ingredients in skincare products that help to manage everything from wrinkles to acne. But is this hemp or marijuana extract as effective as touted? Does it offer any benefits, or is it marketing hype? Below are the facts about CBD gummies and CBD skincare that you need to know.

What Is CBD Oil?

CBD (cannabidiol) is a non-intoxicating compound found in hemp and marijuana plants, extracted in powder form. It is then processed with oil like coconut or olive to enhance its effectiveness as a skincare oil product.

CBD oil made for skincare will not evoke the “high” associate with its counterpart compound THC (tetrahydrocannabinol). While both CBD and THC can be found in hemp and marijuana plants, the hemp plant has a higher CBD and lower THC content than marijuana. At times the THC is so low that it not detectable during testing.

You should not mistake hemp-based CBD oil for hemp seed oil, another effective ingredient found in skincare products. At times, the two are marketed interchangeably, but the CBD oil has a high cannabidiol concentration while hemp seed oil has trace amounts or none.

The FDA regulated the name “CBD” used on products that claim to contain cannabidiol to state the same on the label. The regulated labeling is known as INCI (International Nomenclature of Cosmetic Ingredients). Therefore, products with names, such as CBD-enriched hemp seed oil, might not contain cannabidiol. You can be confident of what you buy is as specified on its label.

CBD For Acne-Prone Skin

According to research, acne is an inflammatory skin condition that could be triggered by various factors. Hence, some people can develop this inflammatory condition because of something they apply or even consume. Studies show that anything that can reduce the swelling and soothe the skin can help manage or treat acne. That is where CBD becomes an alternative solution that can fight the breakouts.

Research shows that CBD oil has anti-inflammatory properties that are beneficial to skin health. As such, CBD can be an active ingredient in skincare products that help treat or manage acne and other related breakouts. It is an ideal option for people with reactive skin.

CBD has been found to potentially lower sebum production, which is a unique quality that can help balance the sebum flow in the skin. But with this encouraging news, scientists still say that more studies are needs for conclusive findings that confirm the full extent of CBD’s benefits in skincare and overall health and wellness.

CBD Oil For Wrinkles And Anti-Aging

Since CBD oil is plant-derived produce, thus, it having antioxidative abilities should not be surprising. The antioxidants can help reduce the signs and impacts associated with aging. The properties counteract free-radicals therein, reducing any inflammation while diminishing noticeable signs like reddish skin tone, wrinkles, and dullness.

With other antioxidant-rich products in the market, it is unwise to claim that CBD is the best option out there. It is one of the many options worth considering if you are keen on finding a safe and better solution to caring for your skin.

CBD Oil For Sensitive Skin

CBD oil is claimed to have soothing compounds since it has been found to have skin-normalizing and skin-calming effects. Such properties are essential in treating and managing skin sensitivity and other related issues like inflammation, reactivity, and redness. With the skin exposed to the elements, different skin types are affected differently by environmental stressors. By applying CBD oil, its soothing mechanism will help keep the skin in check.

Source: http://theleafonline.com/c/lifestyle/2020/11/cbd-oil-and-skin-care-what-you-need-to-know/

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF A Revenue Generating, Canadian Vertically – Integrated Biopharmaceutical Company $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 12:39 PM on Wednesday, November 18th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN: TSX) (AVCN: OTCQX) (0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

Third Quarter Highlights

  • $882K in revenue, an increase of 24% from Q2-2020,
  • Double-digit growth quarter over quarter from Q4-2019
  • Reached a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia. 

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

AGORACOM Small Cap 60: Avicanna $AVCN.ca $AVCNF Medical #Cannabis Trusted By Physicians and Clinicians $TRUL.ca $ACB

Posted by AGORACOM-JC at 3:06 PM on Monday, November 16th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Aras Azadian Chief Executive Officer and Co-Founder of Avicanna discusses the company’s medical cannabis which is trusted by physicians and clinicians. Azadian states, “Only 5% of physicians are currently prescribing Cannabis.” He continues to explain that the medical community has been skeptical of Canadian Licensed producers. Avicanna provides medical and only medical, this bodes well with the medical community.

Avicanna $AVCN.ca $AVCNF Announces Pricing of Public Marketed Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 12:05 PM on Friday, November 13th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

TORONTO , Nov. 13, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has priced its previously announced marketed public offering (the ” Offering “) of units (the ” Units “) of the Company. The Company intends to issue the Units at a price of $0.85 per Unit for gross proceeds of a minimum of $5,000,000 and a maximum of $7,000,000 . Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at a price of $1.20 per share at any time for a period of 36 months following closing of the Offering.

The Offering is being conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed on a “best efforts” basis through the Agents (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected]

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

Avicanna $AVCN.ca $AVCNF Announces Overnight Marketed Public Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 4:38 PM on Thursday, November 12th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Announced that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan in connection with a marketed public offering of units of the Company
  • Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering
  • Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering

TORONTO , Nov. 12, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan (the ” Canadian Jurisdictions “) in connection with a marketed public offering (the ” Offering “) of units (the ” Units “) of the Company.

Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering. Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering. The Offering will be conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

The preliminary short form prospectus is available on SEDAR at www.sedar.com .

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

SOURCE Avicanna Inc.

Avicanna $AVCN.ca $AVCNF Reports Third Quarter 2020 Financial Results and Provides Corporate Update $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 9:05 AM on Thursday, November 12th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Another double-digit increase in revenue quarter over quarter as the company continues to execute on its business plan to commercialize its brands in different geographic markets and product segments.
  • Successful launch of the RHO Phyto line of advanced medical cannabis products nationwide in Canada in partnership with Medical Cannabis by Shoppers Drug Mart Inc.
  • Good Preparation Practices certification and authorization by the National Institute for Drug and Food Surveillance (“INVIMA”) for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia.

TORONTO, Nov. 12, 2020 –Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the third quarter ended September 30, 2020.

Aras Azadian, Chief Executive Officer of Avicanna, commented “We are thrilled to report the tremendous progress our team continues to make in our commercialization and research efforts. During the third quarter, we were able to demonstrate the superiority of our technologies and products with several strategic commercial partnerships but also with an incredibly successful launch of our medical products in the Canadian market.”

Third Quarter Highlights

  • The Company continued to make strides in its strategic commercial initiatives, leading to an increase in revenue of approximately 24% from Q2-2020, continuing the trend of double-digit growth, quarter over quarter from Q4-2019. In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams. Below is a summary of the revenue trend over the last four quarters.
  • Avicanna launched the first product of its RHO Phyto branded line of medical cannabis products on the Medical Cannabis by Shoppers™ (“Shoppers”) platform on August 12, 2020. As of the date of this MD&A, Avicanna has launched its oil drops and sublingual sprays, for a total of four SKUs, through the Shoppers online platform, which offers nationwide service to Canadians.

  • Certain of the RHO Phyto products are participating in the Medical Cannabis Real-World Evidence study (“MC-RWE study”) at the University Health Network (“UHN”). This first-of-its-kind Canadian study is led by Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital, and will examine the efficacy of a select group of medical cannabis products including Avicanna’s RHO Phyto line of products on patient reported outcomes of pain, sleep and anxiety. This specific study is aligned and in parallel with Avicanna’s comprehensive clinical program of other real-world evidence studies involving the RHO Phyto products and clinical trials on its pharmaceutical pipeline with world-class, Toronto-based medical institutions.

  • The Company hosted its third annual symposium, “Medical Cannabis 2.0”, through a virtual format on July 21, 2020. The presentations focused on the evolution of medical cannabis including the Avicanna led advancements in R&D for novel cannabinoid delivery forms and formulations. Presenters including Dr. Ruth Ross (Professor and Chair, Department of Pharmacology & Toxicology, Faculty of Medicine, University of Toronto, Senior Scientist, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health) and Dr. Hance Clarke (Staff Anesthesiologist, Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto). Over 1,000 participants attended the symposium.

  • The Company announced on September 14, 2020 that through Avicanna LATAM S.A.S., the Company’s pharmacy in Bogota has been certified with Good Preparation Practices and authorized by INVIMA for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia. This is the final step in the Company’s fully integrated seed to patient business model in Colombia, which includes cultivation, extraction and manufacturing of pharmaceutical products for the emerging medical market of 50 million people.

  • Avicanna announced on July 24, 2020 that its research collaborators had received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC”). In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation. Avicanna further expanded its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC grant to investigate the neural basis of cannabis-induced toxicosis. The NSERC grants are being used to expand the investigators’ collaborative research with Avicanna at little to no additional cost to the Company.

  • Avicanna and Red White & Bloom Brands Inc. (“RWB”) entered into a distribution agreement (the “Distribution Agreement”) on August 11, 2020, for the exclusive distribution of Avicanna’s hemp-based CBD derma-cosmetic and topical products, branded as Pura H&W™, by RWB in the United States and certain other markets. Under the Distribution Agreement, which has an initial five-year term, RWB will exclusively distribute the Pura H&W™ brand and certain other white label brands at RWB’s direction. In exchange for this exclusivity, RWB is required to pay Avicanna an upfront exclusivity fee in the amount of CAD$250,000 in cash, along with minimum purchase requirements for the rights to be the exclusive distributor of Avicanna’s Pura H&W branded cosmetic products in the US. Under the Distribution Agreement, RWB also has the right to purchase Avicanna’s cosmetic products for distribution into the United States and certain other territories under brands of RWB’s choosing. The initial product offerings under the Distribution Agreement includes body and face lotions, cosmetic creams, gels and serums, as well as soaps and bath bombs.

  • The Company issued an aggregate of 1,952,410 units (the “August Units”) at a price of $1.40 per August Unit, for aggregate gross proceeds of approximately $2.7 million on August 18, 2020. Each August Unit was comprised of one Common Share and one-half of one Common Share purchase warrant, each whole warrant exercisable into one Common Share at a price of $2.00 per share until August 18, 2022, subject to acceleration rights.

  • The Company announced on August 24, 2020 that it completed exports of CBG and CBD isolates into the USA and CBD isolate into Germany. The Company also commenced a pilot tracking system for the export of its active pharmaceutical ingredient products in partnership with TruTrace Technologies Inc.

  • The Company announced on September 4, 2020 that it completed further exports of CBD water soluble formula into the USA and CBD-based cosmetics into the United Kingdom. The Colombian Ministry of Health also granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.

  • The Company announced that it entered into an agreement with a US distributor partner on September 29, 2020, whereby the Company plans to develop certain hemp-derived cannabinoid-based products, including sublingual and sustained release tablets intended for the sleep market for such US distributor. Under the agreement, the Company is developing the intellectual property that forms the basis of the products for a development fee. The Company will receive an ongoing royalty payment based on the gross revenue of the products, and the Company will have the opportunity to supply cannabinoid for the manufacture of the products.

  • During the quarter, the Company incurred general and administrative (G&A”) expenses that total $2,954,438. While the Company’s G&A expenses did marginally increase from the previous quarter, there were several expenses incurred that were one time in nature. Below is a summary of the adjusted EBITDA of the Company over the last four quarters, indicating its continued improvement.
 Q1 2020Q2 2020Q3 2020
Revenue260,903709,468881,956
Adjusted EBITDA*(3,063,524)(3,641,496)(2,608,063)
 
* Adjusted EBITDA is a Non-GAAP measure. Please refer below for a reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA.
  • Subsequent to quarter end, on November 2, 2020, the Company closed a non-brokered convertible debenture financing, pursuant to which it issued convertible debentures (the “Debentures”) with an aggregate Face Principal Amount (as defined below) of $1,100,000 (the “Debenture Financing”). The Debentures bear interest at 8.0% per annum and will mature on the date that is 12 months from the ‎date of issuance, with the first year of interest payable in advance on the date of ‎issuance and capitalized and added into the principal amount (such aggregate amount being, ‎the “Face Principal Amount”). With these funds the Company was able to strengthen its balance sheet and provide the necessary working capital to make a large commercial push in the first quarter of 2021.

Summary of Operations ($CDN)

 Three Months EndedNine Months Ended
 September 30,
2020
September 30,
2019
September 30,
2020
September 30,
2019
     
   $$
Revenues881,9564,9431,852,32745,537
Impairment on inventory(612,105)(612,105)
Inventory Production Costs expensed to Cost of Sales(439,099)(673,387)
Fair value changes in biological assets included in inventory sold(37,818)(607,370)
Unrealized gain/(loss) on changes in fair value of biological assets(1,103,910)723,361
General and administrative2,954,4385,673,5409,064,84312,604,022
Share-based compensation839,954262,4982,455,9161,982,066
Depreciation and amortization419,914326,9831,259,742512,100
Impairment of goodwill2,520,3823,207,227 
Total Expenses(6,734,688)(6,263,021)(15,987,728)(15,098,188)
Other income (loss)378,51272,748(2,117,968)473,646
Net loss before taxes(7,667,152)(6,185,330)(17,422,870)(14,579,005)
Net loss after taxes(7,667,152)(6,185,330)(17,422,870)(14,579,005)
Weighted average number of Common Shares outstanding – basic and diluted26,566,91521,830,15325,348,33019,298,899
Loss per share – basic and diluted(0.35)(0.33)(0.82)(0.84)

Summary of Balance Sheet ($CDN)

  As at September 30, 2020As at December 31, 2019
    
Assets $$
Cash 101,088441,757
Amounts receivable 2,442,4881,202,924
Prepaid assets 652,287704,632
Biological assets 233,644117,367
Inventory 2,084,4141,484,371
Right to use asset 392,516539,710
Property and equipment 19,951,26522,622,322
Intangible assets 10,504,18211,063,900
Derivative asset 1,501,0343,780,000
Investments 7272
Goodwill 3,207,227
Total Assets 37,862,99045,164,282
Liabilities and Equity   
Amounts payable 4,815,1325,177,634
Due to related party 4,952,1243,319,116
Convertible debentures 757,400715,626
Derivative liability 23,434
Lease liability 417,975555,339
Term loan 
Deferred revenue 3,074,7523,323,518
Deferred tax liability 2,173,8342,173,834
Total Liabilities 16,191,21715,288,501
Shareholder’s equity 21,671,77329,875,781
Total Liabilities and Shareholder’s Equity 37,862,99045,164,282

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W: an advanced and clinically tested line of CBD consumer dermacosmetic products; and,
  • RHO Phyto: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its dermacosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation (each such statement a “forward-looking statement”).  Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Avicanna’s current beliefs and assumptions regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Avicanna’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include,  the Company’s revenues to continue to increase through fiscal 2021, the Company’s anticipated activities and results of its various commercial initiatives, its availability and sufficiency of working capital, the anticipated growth of the Company’s business in the first quarter of 2021 and the anticipated further development and improvement of products by the Company.

By identifying such information and statements in this manner, Avicanna is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avicanna to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking statements contained in this press release, Avicanna has made certain assumptions.

Among others, the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: decreases in the prevailing prices for cannabis and cannabis products in the markets in which the Company operates; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; increasing costs of compliance with extensive government regulation; changes in general economic, business and political conditions, including changes in the financial markets ; risks related to licensing, including the ability to obtain the requisite licenses or renew existing licenses for the Company’s existing and proposed operations; dependence upon third party service providers, skilled labor and other key inputs; risks inherent in the agricultural and retail business; intellectual property risks; risks related to litigation; dependence upon senior management; and the other risks disclosed in the Company’s long form final prospectus dated July 8, 2019 and the Company’s annual information form dated April 15, 2020. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Avicanna believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking statements are reasonable, undue reliance should not be placed on such statements, and no assurance or guarantee can be given that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

#Cannabis #Pharmaceuticals Market: Rise in investments by #pharma companies in #CBD to drive the market – SPONSOR: Avicanna $AVCN.ca $AVCNF $CARA $GWPH $TBP.ca $CRBP $PCLO.ca

Posted by AGORACOM-JC at 5:04 PM on Wednesday, November 11th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg
  • Cannabis-based products or the medical marijuana has orchestrated new avenues in the pharmaceuticals industry
  • Pharma companies, small and big, have plowed investments in cannabidiol (CBD), particularly
  • The inroad made by CBD and CBD-based products is unarguably daunting, riding on the wave of staggered legalization of marijuana
  • The game-changing potential that cannabis has made pharma companies nurse new aspirations by setting their sights in the cannabis pharmaceuticals market

Unsurprisingly, some pharma companies for instance, Insys Therapeutics, put robust opposition to legalization of marijuana. The regulatory status on the CBD is markedly unclear and lack worldwide consensus, for instance, differs from state to state in the U.S., and from nation to nation. Nonetheless, over the years there is a clear surge in interest of pharma companies in medical marijuana, given the medical conditions where cannabis hold incredible potential.

FDA-approved CBD-based drugs will stridently see an increase, expanding the horizon in the CBD market. One of the most recalcitrant diseases CBD-based products in cannabis pharmaceuticals market hold potential, as body of preclinical studies have reiterated, is Dravet syndrome and Lennox-Gastaut syndrome (LGS).

A new study on the cannabis pharmaceuticals market scrutinizes the investment potential of some of the aforementioned trends and the ways in which those will shape the growth dynamics during 2020 – 2030.

Cannabis Pharmaceuticals Market: Key Trends

The shape of the cannabis pharmaceuticals market is expected to be molded by the changing dynamic of the regulatory landscape. A large part of negative public perception of cannabis products has been associated with the recreational use of TSH, a key psychoactive element of cannabis. However, as things have begun to change, the global medicinal industry will intensify its efforts in harnessing therapeutic benefits of cannabis.

The cannabis pharmaceutical industry will see new vistas opening up from expanding array of studies that will provide scientific backing of CBD. This is particularly in relation to the safety and uncontested claims of safety. Further, as regulators will treat different categories of cannabis-based product differently and suitably, the risk benefit profile of cannabis pharmaceuticals will become clearer. The scientific rigor for evidence-based medicine will expand the potential of the market and pave way for research in purified cannabidiol.

Two areas where the industry nurses tall hopes in the cannabis pharmaceuticals market are in reducing opioid epidemic, and in managing some of the hard-to-treat conditions such as some cancers. Stakeholders also appreciate the potential of medical cannabis for aesthetic and medical dermatology.

Cannabis Pharmaceuticals Market: Competitive Analysis and Key Developments

The cannabis pharmaceuticals market has seen numerous big shot companies testing new waters in medical marijuana, and making strategic moves to this end. Research units of a few top pharma companies have made moves toward commercializing cannabinoids for medical use. A recent example is research being made by Avicanna for Johnson & Johnson, and by Vapium for Grenco Science.

Another company, notably a spin-off of Abbott Laboratories, AbbVie Inc. has upped its cannabis-related patents. These developments will undoubtedly strengthen the pipeline of cannabis-related drugs, unlocking new prospects in the cannabis pharmaceuticals market. In the course of time, more start-up companies will ramp up their efforts in patenting Cannabis-based tablets and products.

Another behemoth that is making giant stride in the cannabis pharmaceuticals market is Teva Pharmaceuticals. The company recently announced formally that it has entered into distribution deal with cannabis company Canndoc.

Cannabis Pharmaceuticals Market: Regional Assessment

North America has seemed to garner incredible revenue potential among all key geographies in the cannabis pharmaceutical market over the past several years. The groundswell of interest in medical marijuana is circumscribed by favorable regulations in some quarters, notably in parts of the U.S. Intense discussion among industry stakeholders about the taxing and labelling of cannabis-based medicinal products will cement the potential of the regional market. They are keen on increasing the profitability of marijuana-based products. Another promising region is Europe, expanding on the back of rise in investments by pharma companies in CBD.

Read More: https://www.biospace.com/article/cannabis-pharmaceuticals-market-rise-in-investments-by-pharma-companies-in-cbd-to-drive-the-market-/

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 5:54 PM on Wednesday, October 28th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1.  The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. 

2.  Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia. 

3.  Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4.  Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

Avicanna $AVCN.ca Announces Results of Annual General and Special Meeting $WEED.ca $CL.ca $HEXO.ca

Posted by AGORACOM-JC at 6:56 PM on Tuesday, October 20th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Announced that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020.

TORONTO , Oct. 20, 2020 – Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated September 22, 2020 were elected as directors of the Company at Avicanna’s annual general and special meeting of shareholders held on October 20, 2020 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Name of NomineeVotes cast FOR% votes cast
FOR
Votes
WITHHELD
% votes
WITHHELD
Aras Azadian11,304,32199.94%7,3500.06%
Setu Purohit11,304,32199.94%7,3500.06%
Giancarlo Davila Char11,304,21599.93%7,4560.07%
Dr. Chandrakant Panchal11,304,32199.94%7,3500.06%
David Allan White11,304,72199.94%6,9500.06%
Janet Giesselman11,304,72199.94%6,9500.06%
Benjamin Leavenworth11,304,41599.94%7,2560.06%

At the Meeting, the Company’s shareholders also approved the appointment of MNP LLP as the Company’s auditors for the ensuing year, authorized the board of directors to fix the auditors’ remuneration and approved cancellation and re-issuance of certain stock options previously granted to, among others, certain insiders of the Company.

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email [email protected] .

Shifting Trends #CBD and The “Big Pharma” – SPONSOR: Avicanna $AVCN.ca $AVCNF $GWPH $PCLO.ca $CRBP

Posted by AGORACOM-JC at 3:34 PM on Monday, October 19th, 2020

SPONSOR: Avicanna (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place. When we say vertically integrated, we mean it.  Avicanna has 4 fully operating divisions to address the entire market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Avicanna offers you exposure to the entire vertical. Learn More.

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Shifting Trends – CBD and The “Big Pharma”

  • According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively
  • What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones

By: Jamie Moses

With the increasingly immense popularity of CBD and other hemp-based products, the role of naturally extracted medicine in the realm of the global medicinal industry and big pharmaceuticals is growing at a rapid rate. As various studies and researches have proven the beneficial medical impacts of these CBD compounds, their use for the purposes of health and wellbeing is becoming more and more popular. 

The battle between naturally extracted medicine and pharmaceuticals has always been a controversial debate. The role of big pharma” in health and the theories revolving around their shady impacts has always been contentious. Especially after the wide range popularity and cultivation of CBD and its products such as CBD oils, this issue has been highlighted even more. While the big pharma relies on chemicals and synthetics processes for their medicine to interact and work on the human body, natural medicine is more palatable and relies on its structure and nature to be able to bind with the targetted receptors of the body to provide satisfactory results. 

According to a study, more than 42% of the people who use hemp-derived products and CBD have stooped using synthetic drugs and pharmaceuticals to tackle their medical conditions effectively. What this figure shows is a shift of consumers’ confidence towards these natural products rather than the synthetic ones. But why is this change of dynamics occurring so suddenly after the discovery of CBD, when the use of herbal medicine is not at all a new trend and dates back many years? According to WHO, more than half of the world population already uses herbal means for their medical anomalies then why is the impact created by CBD so immense? The answer lies in its qualities and various medical benefits it imparts on the body with little or no side effects. The reasons why people are turning towards CBD oils and plant medicine are provided here.

High costs – Both financial and physical:

Pharmaceutical options may be more effective in terms of their selective activism and rapid action by IV fluids, but they come with a high price. Medical insurances and various critical condition drugs are almost too expensive for every citizen to get. This has created a trend among people to shift towards natural means of medicine and wellbeing and that is where CBD oil has been so much dominant. The lower production overheads and a non-monopolized market have kept the prices of these drugs quite lower as compared to the pharmaceuticals. 

Effectiveness:

According to a study, 52% of the people using CBD products daily or regular;y have reported these drugs to be more effective than the pharmaceuticals. The extended researches done have shown that the first-hand reactions of those people are in fact accurate and CBD really works better for them. It has to do with the fact that CBD oil can activate the ECS system of the body and can antagonize the CB1 and Cb2 receptors binding with them effects to provide good results. Moreover, the non-psychoactive nature of CBD means it does not get you “high: or mind-altered like other cannabis-derivatives THC.

Multi-purpose:

Various studies have shown that CBD is a medical marvel that can be used to treat various medical conditions. People are now using CBD Oil for pain, anxiety, depression, stress, insomnia, neurogenesis, anti-cancer treatments, skin condition, and even heart problems. With the recent researches proving the effectiveness of CBD in these medical anomalies and a wide range of consumption options available to the people, it is no shock that CBD products are upholding the drug market right now.

Side-effects:

According to a study conducted over a span of 30 years gathering information from various hospitals, almost 7% of the people using big pharma drugs are likely to have serious reactions to the medicines and require immediate medical attention. Many more have mild to low side effects after using these pharmaceuticals. This has also caused the people to start using alternatives and look for safer and natural options. 

Final thoughts:

Although the medical effectiveness and easy access is a major factor in the favor of cannabis products, the lingering confusion regarding its legal status and dosage regulations still cause hurdles in the way. With the recent law changes, the hemp cultivation has seen an uprise and only by educating people more can this industry of herbal medicine become more effective and provide for the betterment of mankind. 

Source: https://artvoice.com/2020/08/17/shifting-trends-cbd-and-the-big-pharma/